Conceptual vector illustration. Human diseases. Stop cancer
Its now well established that obesity, visceral (belly) fat and type 2 diabetes (i.e., metabolic dysfunction) increase a persons risk for developing certain cancers. What is only beginning to be appreciated is that cancer patients that have underlying metabolic dysfunction have much worse outcomes and seriously increased mortality rates. This suggests that metabolic hormones play an important role in cancer progression, and could be valuable targets in cancer treatment.
A variety of chronic, adverse health issues are associated with metabolic dysfunction, including type 2 diabetes, cardiovascular diseases, Alzheimers, and most notably cancer. Metabolic dysfunction is linked with worse outcomes for at least 13 types of cancers and is associated with a 33% elevated risk of death from cancer in the US. Of all the various cancer types, some of the most common are highly sensitive to dysregulated metabolic hormones (insulin, leptin, adiponectin) and chronic inflammation stemming from overweight/obesity, pre-diabetes, type 2 diabetes and metabolic syndrome. An estimated 630,000 patients in the United States alone were diagnosed in 2014 with an obesity-related cancer, including breast, prostate, and colorectal cancers. Yet, only now are oncologists and researchers beginning to pay close attention to the profound influence systemic metabolic dysfunction has on cancer progression and patient outcomes.
The nexus of cancer and metabolic dysfunctionMetabolic dysfunction leads to dysregulated hormones that impact known oncogenic pathways causing tumors to grow faster with greater metastatic potential, and may even be implicated in cancer treatment resistance. The metabolic hormone insulin, as well as leptin and adiponectin (aka adipokines), signal through validated oncogenic pathways, including PI3K/Akt/mTOR, MAPK, ERK, JNK, Notch, and STAT3, and trigger deleterious downstream effects such as cell proliferation, migration, angiogenesis, stem cell protection, and metastatic potential. Ultimately, these downstream effects drive tumor growth and metastasis. Moreover, systemic metabolic dysfunction dysregulates the tumor immune microenvironment leading to immune suppression possibly rendering the tumor resistant to cancer treatment.
Sadly, you dont have to be overweight to have metabolic dysfunction. People who maintain a healthy weight according to their body mass index (or BMI) can still have systemic metabolic dysfunction, depending on how their body fat is distributed. These individuals are also at a higher risk of developing cancer, one major example of this being in post-menopausal women and breast cancer. Furthermore, cancer therapies themselves can induce metabolic dysfunction (e.g., hyperglycemia, hyperinsulinemia, weight gain, insulin resistance) which can impact the patients quality of life and even lead to treatment failure.
Why targeting gene mutations isnt enoughCurrent cancer treatments tend to target specific mutations or dysregulated pathways in tumor cells with the goal of blocking cell proliferation and reducing tumor burden. However, as long as metabolic dysfunction is stimulating key oncogenic pathways, oncologists administering these treatments will be fighting a losing battle. Studies with diet and exercise suggest that standard treatments may be more effective if they are administered simultaneously with measures to reduce metabolic dysfunction in cancer patients. This approach addresses the disease on two fronts: molecularly targeted chemotherapeutics arrest cell proliferation and can shrink the tumor size, while restoring normal metabolic hormone levels relieves the external stimulation on oncogenic signaling pathways. Not only does this combination approach impede multiple cancer drivers at both the systemic and cellular levels, but it also improves patients quality of life by boosting their strength and possibly lessening side effects from treatment.
It is now more important than ever that standard cancer treatments account for the critical role that metabolic dysfunction plays in patients prognosis. Rates of obesity, pre-diabetes and type 2 diabetes are on the rise worldwide, driven by poor diets, sedentary lifestyles, and even reduced activity during the Covid-19 pandemic. Furthermore, metabolic dysfunction and cancer are associated with aging, and retiring baby boomers make up a massive aging segment of our population. This growing population of aging individuals combined with an increase in metabolic dysfunction creates the perfect storm in which many more people are likely to develop highly aggressive forms of cancer in the coming years.
How to treat a cancer patient with metabolic dysfunction?When a person with metabolic dysfunction discovers they have cancer, they can work with an endocrinologist or dietician to develop healthier lifestyle habits, such as weight loss, better diabetes control, improved nutrition, and regular physical activity all of which help the patient better tolerate chemotherapy, and improve the treatment outcomes. However, sticking to a rigorous diet and exercise regimen can be challenging for patients, especially while they are undergoing chemotherapy. While adopting healthy habits should always be a goal, cancer patients could benefit from pharmacological options that treat systemic metabolic dysfunction more predictably and reliably to provide a complementary, one-two punch with standard of care cancer therapies so they have a better shot at working. Although there are no drugs on the market specifically targeting this population, the type 2 diabetes drug metformin has been clinically studied in this population, with mixed results.
Treating the patient, not just the cancerWeinbergs The Hallmarks of Cancer got it right a multi-faceted approach to treating cancer is the way forward. Metabo-oncology is the emerging area of research dedicated to understanding and developing treatments for cancers that are sensitive to metabolic dysfunction. A steadily-growing body of clinicians are speaking out on the role of metabolic dysfunction and its implications on cancer patient treatment and clinical outcomes.
Justin Brown PhD, assistant professor and director of the Cancer Metabolism Program at the Pennington Biomedical Research Center in Louisiana is a leader in the field researching how metabo-oncology principles can be put into clinical practice. From Dr. Browns perspective, the diagnosis of cancer triggers two reactions: on one hand, an individual becomes motivated to do everything in their power to maximize the probability for a good outcome; on the other hand, the diagnosis is overwhelming, stressful, and terrifying. Most patients experience some combination of both reactions, and this is where healthy lifestyle habits can be a powerful, enabling tool.
Dr. Brown believes that oncologists should provide the right information about lifestyle choices to the right patient at the right time. When a patient indicates that they are ready, physicians could then initiate a patient-centered discussion about the benefits of pursuing a healthy lifestyle. Once a patient decides they want to adopt a healthier lifestyle, doctors should put the patients in contact with experts (endocrinologists, dieticians) to help improve clinical success.
In reality, however, while oncologists and their patients generally recognize the importance of healthy lifestyle habits, in a 2019 survey conducted by the American Society of Clinical Oncology, oncologists only reported counselling patients about weight management, healthful eating, and physical activity about 40-60% of the time, due to a lack of training, limited referral options, and lack of third-party reimbursement for diet and exercise counseling.
Thats why treating cancer patients with concomitant metabolic dysfunction remains a major challenge for oncologists. The work of a key opinion leader in this field, Emily Gallagher, MD, PhD demonstrates this well. Dr. Gallagher is an endocrinologist at Mount Sinai in New York who specializes in treating cancer patients with metabolic dysfunction. When Dr. Gallagher treats her patients, she never takes a one-size-fits-all approach to addressing their metabolic issues. Instead, she considers the underlying medical reason patients were referred to her, the type of cancer they have, and the type of treatment they are receiving. She considers pre-existing conditions, like type 2 diabetes, current lifestyle, and disease symptoms when devising a treatment regimen that she believes will be most effective. She sets short-term and long-term goals for her patients and follows up regularly to help keep them on track, and encourages them to see a diabetes educator/dietitian to further encourage positive lifestyle changes.
From Dr. Gallaghers perspective, when patients have metastatic cancer, their non-cancer background conditions often go under-treated. But, by ignoring systemic metabolic dysfunction, clinical oncologists may inadvertently be contributing to their patients disease progression. Therefore, its important that oncologists pay close attention to the metabolic health of their cancer patients and monitor for endocrine side effects (hyperglycemia, hyperinsulinemia, obesity/weight gain) induced by the cancer drugs they prescribe. This is why it makes sense to refer these patients to endocrinologists who may have already developed strategies to address these problems. Whats more, by having the oncology team reinforce the importance of systemic metabolic health, it communicates to the patients that their treatment strategy is being administered by a team of doctors using a whole-patient strategy.
While treating physicians know that obesity/systemic metabolic dysfunction leads to worse outcomes for their cancer patients, they face multiple challenges in addressing it: limited pharmacologic interventions that can effectively treat patients metabolic issues, lack of training in the methods endocrinologists use to address these issues, and no payer incentives to encourage better lifestyle choices. While we wait for effective pharmaceutical interventions that can reliably address these issues, anti-diabetic medications and diet and exercise will have to do. Addressing systemic metabolic dysfunction in cancer patients requires communication between diverse medical experts and scientific disciplines. Incorporating a multi-disciplined approach to treating cancer should help foster better clinical practices for cancer patients and improved outcomes for patients with cancers sensitive to metabolic hormones.
Photo: Main_sail, Getty Images
- The Pandemic and Childhood Weight Gain | Tufts Now - Tufts Now - January 5th, 2021
- How the American Diet Turbocharges COVID-19 - Mother Jones - January 5th, 2021
- Why do some people find it harder than others to lose weight? - The Guardian - January 5th, 2021
- After magazine calls obesity 'healthy', here is understanding when it crosses the line - Times Now - January 5th, 2021
- 80% of the Covid deaths in Yucatan involved hypertension, diabetes, or obesity - The Yucatan Times - January 5th, 2021
- Obesity, the other risk of American football - The Press Stories - January 5th, 2021
- Chronic inflammation of obesity: How it affects blood vessel cells - TheHealthSite - January 5th, 2021
- Brown fat may protect you against cardiac, metabolic conditions: How is it different from white fat? - TheHealthSite - January 5th, 2021
- A Recipe for Homemade Obesity: The Association Between Depression, Obesity, and Cognitive Deficits - Psychiatric Times - January 5th, 2021
- Aspirin Use for Venous Thromboembolism Prevention Is Safe and Effective in Overweight and Obese Patients Undergoing Revision Total Hip and Knee... - January 5th, 2021
- Assessing the Link Between Sugary Drinks and Cancer - Pharmacy Times - January 5th, 2021
- Dr. Edward Mason All Obituaries - The Gazette - January 5th, 2021
- Researchers discover blood vessel cells that triggers harmful inflammation in obese mice - Study Finds - January 5th, 2021
- Obesity Surgery Devices Market Statistics, Facts and Figures, Size, Trend and Forecast by 2026 | Johnson & Johnson, Medtronic, Apollo Endosurgery ... - January 5th, 2021
- Chonky Kitty: The Internets Unhealthy Obsession Over Obese Cats - Nature World News - January 5th, 2021
- Nottingham declared one of UK's obesity hotspots in latest NHS report - Nottinghamshire Live - January 5th, 2021
- Influencers May Face Fines as China Tackles Obesity and Food Waste - The New York Times - December 28th, 2020
- Diabetes + Obesity = Diabesity: The Enemy Within You - Hindustan Times - December 28th, 2020
- Scientists Discover a Gene to Stay Thin Protects Against Diet-Induced Obesity - SciTechDaily - December 28th, 2020
- UK restricting promotions on 'unhealthy food' at supermarkets, retailers in bid to fight obesity - Fox News - December 28th, 2020
- COVID-19 and obesity: a clear and present danger in younger patients - The Daily Star - December 28th, 2020
- Obesity is associated with shorter telomere length in prostate stromal cells in men with aggressive prostate cancer - DocWire News - December 28th, 2020
- University of York leads 6 million bid to cut child obesity | York Press - York Press - December 28th, 2020
- Womens Health: Fighting obesity - NEWS10 ABC - December 28th, 2020
- Bariatric Surgery Might Reduce Severity of COVID-19 Infection - Medscape - December 28th, 2020
- Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial - PRNewswire - December 28th, 2020
- Clemson team hopes research will lead to more varieties of lentils - SCNow - December 28th, 2020
- Study links metabolic syndrome to higher cardiovascular risk in patients with psoriasis - National Institutes of Health - December 28th, 2020
- Obesity and smoking as risk factors for invasive mechanical ventilation in COVID-19: A retrospective, observational cohort study - DocWire News - December 28th, 2020
- 6 common myth around weight management and obesity, busted! - Times Now - December 28th, 2020
- Britain to restrict promotion of unhealthy food from April 2022 - Reuters - December 28th, 2020
- Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance,... - December 28th, 2020
- Long life: Cities across the US where people live the longest include San Francisco and Boulder - USA TODAY - December 28th, 2020
- Breast Cancer Survival Disparities: Need to Address Obesity - Medscape - December 12th, 2020
- Data shows link between obesity and developing severe COVID-19 symptoms - KTIV - December 12th, 2020
- Former Bin Laden subordinate released after judge agrees he's too obese to survive coronavirus - Fox News - December 12th, 2020
- Study finds more years of obesity tied to higher risk of diabetes - Atlanta Journal Constitution - December 12th, 2020
- The Hidden Dangers Of Excessive Fat: Know Why You Need To Shed Those Extra Kilos - NDTV - December 12th, 2020
- Obesity in children might be due to genetic variant resulting in less leptin production - Hindustan Times - December 12th, 2020
- Study finds Pre-K students on South Texas border have higher rates of obesity related to poverty - Border Report - December 12th, 2020
- Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, MD, and Lynn Tetrault, JD, to its Board of Directors - BioSpace - December 12th, 2020
- FoodTech startup treats obesity, diabetes through individualized AI-driven nutrition plans - CTech - December 12th, 2020
- Tips to help families navigate the growing problem of childhood obesity - WNEP Scranton/Wilkes-Barre - December 3rd, 2020
- 13.2% of 10- to 17-year-olds in Maine are obese, study finds - The Center Square - December 3rd, 2020
- 13.7% of 10- to 17-year-olds in New Hampshire are obese, study finds - The Center Square - December 3rd, 2020
- Tips to help families navigate the growing problem of childhood obesity - KESQ - December 1st, 2020
- 10.7% of 10- to 17-year-olds in New York are obese, study finds - The Center Square - December 1st, 2020
- 20.4% of 10- to 17-year-olds in Tennessee are obese, study finds - The Center Square - December 1st, 2020
- Food Insecurity Increasingly Tied to Obesity in the United States - Food Tank - December 1st, 2020
- Transomics analysis reveals allosteric and gene regulation axes for altered hepatic glucose-responsive metabolism in obesity - Science - December 1st, 2020
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity... - December 1st, 2020
- PCOS and diabetes risk increases with obesity here's how they affect fertility in women - Firstpost - December 1st, 2020
- Higher COVID-19 Risk Leading More Patients With Obesity To Weight Loss Surgery - CBS Boston - November 26th, 2020
- Shift in language to help reduce obesity stigma - WA Health - November 26th, 2020
- Anti-Obesity Day 2020: Simple ways to eat smart and beat weight gain - The Indian Express - November 26th, 2020
- DDRC DIVING AND OBESITY SURVEY - DIVE Magazine - November 26th, 2020
- The Link Between Obesity and Puberty - Michigan Medicine - November 25th, 2020
- Evaluating Innovative Health Care Solutions for Obesity - Harvard Business Review - November 25th, 2020
- Researchers Discover Hormone That Can Curb Appetite and Help Deal With Obesity - Science Times - November 25th, 2020
- Gut hormone that regulates fat found abnormal in obesity - India New England - November 25th, 2020
- Research shows bariatric surgery may reduce severity of Covid-19 in patients with obesity - Hindustan Times - November 25th, 2020
- More Obese Patients Seeking Weight Loss Surgery To Reduce COVID-19 Risk - CBS Boston - November 25th, 2020
- Obesity is still on the rise among American adults - Harvard Health - Harvard Health - November 25th, 2020
- Association Between Clogged Arteries and Body Size Phenotype? Study Finds, It Varies - AJMC.com Managed Markets Network - November 25th, 2020
- Parents' wake up call as obesity and sunburn risks rise - Daily Mercury - November 25th, 2020
- Executive summary: learning from local authorities with downward trends in childhood obesity - GOV.UK - November 25th, 2020
- Study: Gut hormones' regulation of fat production abnormal in obesity, fatty liver disease - University of Illinois News - November 25th, 2020
- Brands call for alternatives to online junk food ads ban - The Guardian - November 25th, 2020
- As Obesity Soars, a Mayo Clinic DNA Study May Have Cracked The Cause - Observer - November 22nd, 2020
- Looking at the unintended consequences of obesity campaigns - Contemporary Pediatrics - November 22nd, 2020
- In Those With Obesity, Will Losing Weight Cut COVID-19 Severity? - Medscape - November 22nd, 2020
- Pupil measurements accelerated amid fears of obesity crisis - The Independent - November 22nd, 2020
- Bay Area is home to two of the least sinful cities in the U.S. - The Mercury News - November 22nd, 2020
- Epidemiological and immunological features of obesity and SARS-CoV-2 - DocWire News - November 22nd, 2020
- Obesity does not adversely impact the outcome of unicompartmental knee arthroplasty for osteoarthritis: a meta-analysis of 80,798 subjects - DocWire... - November 22nd, 2020
- Obesity Linked to Higher Risk of Covid-19 Infection - Contagionlive.com - November 22nd, 2020
- Horse vet gives fresh scoop on the equine obesity epidemic - Horsetalk - November 22nd, 2020
- New podcast episode from Morris Animal Foundation highlights the equine obesity epidemic - EQUUS Magazine - November 22nd, 2020
- Effects of Body Mass Index on Peri-operative Outcomes in Patients Undergoing Anterior Cervical Discectomy and Fusion Surgery - DocWire News - November 22nd, 2020
- Nearly 4 billion people likely to be overweight, 1.5 million obese by 2050 with current diet trends - Times Now - November 22nd, 2020